Bristol-myers Squibb Pharma Company

Bristol-myers Squibb Compnay

Merck Sharp + Dohme Corp.

Infinity Pharmaceuticals, Inc.

Infinity Discovery, Inc.

Wei Deng

Albert Jean Robichaud

Taekyu Lee

Wenting Chen

Ian S Mitchell

David M Zawrotny

Christopher D McClung

Simon Nicolas Haydar

Michael G Yang

Emilie J Calvello

Emilie J B Calvello

Christopher D Mc Clung

Emile J B Calvello

Parthasarathl Rajagopalan

Alfredo C Castro

Richard Eric Olson

Christopher J Dinsmore

Thomas P Maduskuie, Jr

Edward Holson

Michael J Grogan

Tao Liu

Daniel A Snyder

Brian T Hopkins

Ruth Richmond Wexler

Dennis John Underwood

David Joseph Guerin

Jason David Katz

Jianmin Fu

Christopher Francis Thompson

Norman Kong

Mark E Scott

Peter H Fuller

Lorin Andrew Thompson

Andrew J Tebben

Asimina T Georges Evangelinos

Michael Andrew Foley

Hong Liu

Christian C Fritz

Luis E Torres

Hongbo Zeng

Danielle Falcone

Nii O Koney

Nenghui Wang

Zhixiang Zheng

Yunfeng Bai

Yumei Liu

Linping Zhang

Lin-Chen Yu

David A Mann

Kristopher M Depew

Lisa A Marcaurelle

Andrew A Wylie

Nafeeza Hafeez

Dennis J Underwood

Michael A Foley

Edward B Holson

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors

One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

The present application provides novel compounds according to Formula (I): including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).

Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists

The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Substituted heterocycle fused gamma-carbolines

The present invention is directed to certain novel compounds represented by structural Formula (I)or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

Substituted heterocycle fused &#x3b3;-carbolines

The present invention is directed to novel compounds represented by structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HTreceptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.

Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists

The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

This invention relates to novel carbocycles and heterocycles having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

Succinoylamino carbocycles and heterocycles as inhibitors of a-&bgr; protein production

Growing community of inventors

Lexington, MA, United States of America

Wei Deng